Diabetes

Using results from the Rx for Change program in Pittsburgh, Pennsylvania, researchers explored an integrative approach to cardiometabolic disease management among Black patients.

However, caution with empagliflozin use should be applied for patients previously taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

Certified diabetes care and education specialists and clinical pharmacists are essential members of diabetes care teams.

Investigators emphasize the importance of proper education regarding diabetes and continuous glucose monitors.

In association with patients’ race, ethnicity, and social determinants of health, researchers explored the off-label prescribing of GLP-1s approved for type 2 diabetes.

Sustainable CGM counseling combines pharmacist expertise, technician support, multimodal education, and policy advocacy to improve patient outcomes in diabetes care.

Targeted education and hands-on experience are helping pharmacists gain the confidence needed to guide patients in continuous glucose monitoring.

Recent studies reveal that while diabetes technology use rises, glycemic control in type 1 diabetes patients remains low, highlighting significant disparities.

In the context of the COVID-19 pandemic, researchers investigated how insulin use and glycemic control were associated among patients with type 2 diabetes.

Pharmacists play a key role in guiding patients on GLP-1 and dual agonist therapies, supporting safe use, managing adverse effects, and promoting long-term treatment success.

As continuous glucose monitoring becomes more common, pharmacists are essential in patient education but face barriers of time, training, and reimbursement.

Leveraging staff support, multimodal education, and policy change can make CGM counseling more sustainable in community pharmacies.

Among patients with type 2 diabetes, researchers explored how tirzepatide or semaglutide use was associated with first-time reports of optic nerve or visual pathway disorders.

Pharmacists can build confidence with CGMs through hands-on experience, continuing education, and strong support from employers, peers, and manufacturers.

Investigators found that health care costs rose despite the benefits seen with starting semaglutide for patients with and without diabetes.

Pharmacists are key to CGM education, but time, training, and reimbursement remain major barriers.

Compounding pharmacies help meet patient needs by formulating alternative versions in the face of drug shortages but are no longer allowed to compound them.

Investigators find modest improvements in body weight at week 26 for CT-868 compared with the placebo.

New research shows metformin's inconsistent neuroprotective effects against Alzheimer disease, challenging its role in diabetes management for cognitive health.

Patients with type 2 diabetes and moderate cardiovascular risk had a higher rate of major heart-related events when treated with sulfonylureas.

Study data reveal that women with low blood glucose levels before conception face higher risks of adverse pregnancy outcomes, emphasizing the need for screening and education.

In a study, investigators say that a patient’s financial health should be considered when starting treatment for type 2 diabetes.

Among patients with cirrhosis receiving diuretic therapy, researchers explore the association between SGLT-2 inhibitors and the risk of serious liver outcomes.

Researchers explored how the GLP-1 medications semaglutide and tirzepatide impact incidence rates in a variety of health-related outcomes.

The FDA approves Kirsty, an interchangeable biosimilar insulin, enhancing diabetes treatment options and accessibility for patients.